Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 44 P52 | DOI: 10.1530/endoabs.44.P52

SFEBES2016 Poster Presentations Bone and Calcium (20 abstracts)

Continuous synthetic PTH1-34 replacement therapy in the treatment of autosomal dominant hypoparathyroidism type 1

Vidhya Jahagirdar 1 , Heather Stirling 2 & Sailesh Sankar 1

1Department of Diabetes and Endocrinology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK; 2Department of Paediatrics, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.

A young female with autosomal dominant hypoparathyroidism type 1 who had inherited the gene defect from her mother was under the care of paediatric endocrinologist. Since childhood she was on a large dose of calcium (elemental calcium 5 g) along with Vitamin D, potassium and magnesium replacements. Despite careful monitoring there was significant fluctuations in serum calcium levels which led to recurrent hospital admissions with hypercalcaemia and acute kidney injury or severe symptomatic hypocalcaemia. She presented frequently with hypocalcaemic seizures, one such event leading to fall, fracture of occipital bone and subdural haematoma. Ultrasound of the renal tract showed nephrocalcinosis and she had developed stable chronic kidney disease. At the age of 17 she was commenced on subcutaneous recombinant human parathyroid hormone (rhPTH1-84) 100 μg once daily which was switched to subcutaneous teriparatide (rhPTH1-34) 20 μg twice daily. Despite this there was huge fluctuation in serum calcium levels. Hence she was commenced on continuous subcutaneous infusion of teriparatide via omnipod insulin pump. The daily calcium and Vitamin D requirement and the wide fluctuations in calcium were reduced and hospital admissions due to hypocalcaemic seizures were avoided. Although twice daily rhPTH1-34 provides acceptable treatment of hypoparathyroidism in most patients, there is often nonphysiological fluctuation in serum calcium. To date, continuous subcutaneous delivery of PTH1-34 via pump provides the closest approach to physiological replacement therapy for hypoparathyroidism.

Volume 44

Society for Endocrinology BES 2016

Brighton, UK
07 Nov 2016 - 09 Nov 2016

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.